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Abstract
The P2X7 receptor, originally known as the P2Z receptor due to its distinctive functional properties, has a structure character-
istic of the ATP-gated ion channel P2X receptor family. The P2X7 receptor is an important mediator of ATP-induced puriner-
gic signalling and is involved the pathogenesis of numerous conditions as well as in the regulation of diverse physiological 
functions. Functional characterisations, in conjunction with site-directed mutagenesis, molecular modelling, and, recently, 
structural determination, have provided significant insights into the structure–function relationships of the P2X7 receptor. 
This review discusses the current understanding of the structural basis for the functional properties of the P2X7 receptor.
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Introduction
The concept of P2 purinergic receptors for extracellular ATP 
(and ADP), when proposed by Burnstock, the pioneer of 
purinergic signalling, was met with extraordinary resistance 
[1]. Today, it is firmly established that ATP-induced puriner-
gic signalling, mediated by two structurally and functionally 
distinctive subfamilies of P2 purinergic receptors known as 
ligand-gated ion channel P2X receptors and G-protein-cou-
pled P2Y receptors, is a widely used signalling mechanism 
[2]. The P2X7 receptor was initially named the P2Z receptor 
due to its unique functional properties; receptor activation 
requires > 100 μM ATP, two orders of magnitude higher than 
concentrations required for activation of other P2 receptors, 
and prolonged receptor activation induces membrane per-
meabilisation and eventually cell death, earning its name of 
the cytolytic receptor [3, 4]. When the receptor manifesting 
these hallmark properties was molecularly identified, it was 
found to have a high degree of sequence homology with 
the six ion channel-forming P2X receptors (P2X1–P2X6), 
in addition to the same membrane topology consisting of 
intracellular N- and C-termini and two transmembrane 
domains linked by a large extracellular domain, albeit with 
an extended C-terminus. It was therefore united with the 
P2X receptor family as the seventh member [5–7]. The 
extensive research over the past decades, aided by P2X7-
deficient mice and P2X7-specific antagonists, has consider-
ably advanced our understanding of P2X7 receptor function 
in mammalian cells. The P2X7 receptor plays a critical role 
in mediating immune responses, bone remodelling, neuron-
glia communication, and other physiological processes, and 
is also important in the pathogenesis of many conditions, 
including autoimmune diseases, neurodegenerative diseases, 
mood disorders, and cancers, making it an attractive thera-
peutic target (e.g. [8–24]).
The structure–function relationships of the P2X7 recep-
tor were mostly inferred from mutagenesis and functional 
studies of other P2X receptors [25], but have recently 
been revolutionised by progress in the structural biology. 
The breakthroughs in determining the structures of the 
zebrafish P2X4 receptor in apo and ATP-bound states 
[26, 27] allowed us for the first time to directly see how 
ATP binds to the P2X receptor and opens the ion chan-
nel. Structures of P2X7 receptors have been determined 
in recent years, including the intracellularly truncated 
chicken and giant panda P2X7 receptors [28, 29], and 
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notably the full-length rat P2X7 receptor [30]. Increased 
structural information offers an exciting opportunity to 
understand in molecular detail how the P2X7 receptor 
operates. In this review, we discuss structural and func-
tional studies of P2X7 receptors and provide an overview 
of the current understanding of the structural basis for the 
functional properties of this physiologically and therapeu-
tically important receptor.
The overall receptor architecture
The transmembrane and extracellular domains of P2X recep-
tors, as anticipated from their high sequence homology, have 
similar secondary and quaternary structural arrangements, 
which have been borne out by receptor structures. As illus-
trated in Fig. 1a for the rat P2X7 receptor, both transmem-
brane domains (TM1 and TM2) are α-helical (α1 and α6, 
respectively) and the extracellular domain contains fourteen 
β-strands (β1–β14) and four α-helices (α2–α5). The overall 
structure of the transmembrane and extracellular domains 
of the receptor subunit resembles the shape of a leaping dol-
phin, with the extracellular domain making the main body, 
including the head, upper body, lower body, left flipper, right 
flipper, and dorsal fin, and the transmembrane domains the 
fluke (Fig. 1a). Multiple anti-parallel β-strands, including 
β1, β2, β8, β9, β11 and β12 in the lower body and β13 and β14 
in the upper body, form rigid structures or the so-called 
connecting rods [25] that link the extracellular domain to 
the TM1 and TM2 α-helices, respectively (Fig. 1a). The 
intracellular domains of the P2X receptors, particularly 
the C-terminus, noticeably differ in length and exhibit low 
sequence similarity. In the rat P2X7 receptor, the N-terminus 
has one α-helix (α0) and two β-strands (β−1 and β0) and the 
C-terminus, excluding the segment missing in the structure 
 (Ser443-Arg469 in the apo state or  Ser443-Arg471 in the ATP-
bound state), encompasses further ten α-helices (α7–α16) and 
four β-strands (β15–β18) (Fig. 1a).
The P2X receptor is a trimer, differing from other 
extracellular ligand-gated ion channels such as the tetra-
meric ionotropic glutamate receptor and the pentameric 
nicotinic acetylcholine receptor [31]. The homo-trimeric 
Fig. 1  The P2X7 receptor architecture. a The secondary structure of 
single subunit in the rat P2X7 receptor in the apo state. The trans-
membrane domains (TM1 and TM2) are α-helical (α1 and α6, respec-
tively), and the extracellular domain contains fourteen β strands (β1–
β14) and four α-helices (α2–α5). The shape of the extracellular and 
transmembrane domains together resembles a leaping dolphin. Inserts 
shown in the right panel: the connecting rods that are formed by mul-
tiple anti-parallel β-strands in the upper and lower bodies and link the 
extracellular domain to the TM1 and TM2 domains (top); the N-ter-
minus that is shown to contain one α-helix (α0) and two β-strands 
(β−1 and β0) (middle); and the C-terminus, excluding the missing 
segment (S443-R469), that encompasses ten α-helices (α7–α16) and 
four β strands (β15–β18) (bottom). The distal C-terminus in each subu-
nit, including α9–α16 and β16–β18, constitutes the cytoplasmic ballast 
that contains one GDP-bind site and two  Zn2+-binding sites. b The 
quaternary structure of the trimeric rat P2X7 receptor in the apo 
and closed state, with each subunit highlighted in different colour. 
Three extracellular domains are intervened with each other to form 
the extracellular part. The transmembrane part includes six α-helices, 
with the three TM2 (α6) α-helices lining the ion-permeating pathway 
in the centre and the three TM1 (α1) α-helices on the periphery. The 
cytoplasmic ballast rests beneath the transmembrane domains of a 
neighbouring subunit. Insert in the lower panel: the β−1 and β0 in the 
N-terminus of two adjacent subunits, together with β15 and α8 in the 
proximal C-terminus of the third subunit, forms the cytoplasmic cap. 
The cysteine-rich domain, linking the TM2 α-helix to the cytoplasmic 




rat P2X7 receptor consists of extracellular, transmem-
brane, and cytoplasmic parts [30] (Fig. 1b). In the extra-
cellular part, three extracellular domains are intimately 
intervened with each other via extensive inter-subunit and 
intra-subunit interactions and form the ligand-binding 
sites. The transmembrane part includes six α-helices, 
with the three TM2 α-helices lining the ion-permeating 
pathway in the centre of the receptor and the three TM1 
α-helices on the periphery. There are three separate 
structural components in the cytoplasmic part [30]. Two 
β-strands in the N-terminus, β−1 from one subunit, and 
β0 from the other, together with β15 and α8 in the proxi-
mal C-terminus of the third subunit, form a cytoplasmic 
cap [30] (Fig. 1b). A similar structural component has 
been identified in the human P2X3 receptor containing 
intracellular membrane-juxtaposing domains [32]. The rat 
P2X7 receptor structures reveal palmitoylation of several 
residues, including  Cys4 in the N-terminus and  Ser360, 
 Cys362,  Ser363,  Cys374, and  Cys377 in the P2X7-specific 
cysteine-rich domain (CRD) in the proximal C-terminus, 
named the C-cys anchor [30] (Fig. 1a). This domain link-
ing the TM2 to the cytoplasmic cap anchors both of them 
to the plasma membrane, functioning as a hinge. Finally, 
the distal C-terminus in each subunit, including β16–β18 
and α9–α16, forms a ballast-like structure resting beneath 
the transmembrane domains of the neighbouring subu-
nit [30] (Fig. 1a, b). Intriguingly, the cytoplasmic bal-
last contains a GDP-binding site and two  Zn2+-binding 
sites (Fig. 1a) but their functional and physiological role 
remains to be established.
The extracellular inter‑subunit ATP‑binding 
pocket
Earlier studies analysing the single channel activation kinet-
ics [33] and the ATP concentration-current response curves 
[34] suggest that the P2X receptor contains three ATP-bind-
ing sites. Extensive mutagenesis studies of mammalian P2X 
receptors, particularly the P2X1, P2X2, and P2X4 receptors, 
identified a subset of conserved residues in the extracellu-
lar domain that are crucial for receptor activation, includ-
ing six hydrophilic residues corresponding to  Lys64,  Lys66, 
 Thr189,  Asn292,  Arg294, and  Lys311 in the rat P2X7 receptor, 
and provide further evidence to suggest that ATP binding 
occurs at the interface between two subunits [25]. The ATP-
bound structures of the zebrafish P2X4, human P2X3, and 
rat P2X7 receptors [27, 30, 32] consistently support these 
ATP-binding features and, moreover, delineate how these 
residues coordinate ATP binding. The inter-subunit ATP-
binding pocket is made up by the head, upper body, and 
left flipper of one subunit, and the lower body and dorsal 
fin of the adjacent subunit, as illustrated for the rat P2X7 
receptor (Fig. 2). ATP binds at the apex of this inter-subunit 
pocket, assuming a U-shaped configuration and interacting 
with  Lys64,  Lys66, and  Thr189 in the lower body and  Asn292, 
 Arg294, and  Lys311 in the upper body (Fig. 2b). More specifi-
cally, the γ-phosphate group interacts with  Lys66,  Arg294, and 
 Lys311, the β-phosphate group with  Asn292, and the adenine 
with  Thr189.  Lys64 is located in the centre of the three phos-
phate groups and forms hydrogen bonds with all of them, 
as does the corresponding  Lys70 residue in the ATP-bound 
Fig. 2  The extracellular inter-subunit ATP-binding pocket. (a) The 
quaternary structure of the rat P2X7 receptor in the ATP-bound and 
open state. ATP binds to the three subunit interfaces, inducing for-
mation of three lateral fenestrations above the membrane as indicated 
by the dotted circle. (b) ATP binds at the apex of this inter-subunit 
pocket in the rat P2X7 receptor, formed by the head, upper body, and 
left flipper of one subunit (A) and the lower body and dorsal fin of 
the adjacent subunit (B). ATP binding is coordinated by K64, K66, 
and T189 in the lower body and N292, R294, and K311 in the upper 
body. The hydroxyl groups at positions 2′ and 3′ of the ribose are out-
ward-facing. L191, K193, R276, and R277 in the lower body, I214 
and I228 in the dorsal fin, K145 in the head, D280 and F288 in the 
left flipper, and E186 and N187 in the right flipper in the rat P2X7 
receptor contribute to determining ATP sensitivity. K127 in the head 
and N284 in the left flipper are responsible for the greater agonist 
sensitivity of the rat P2X7 receptor than the mouse P2X7 receptor
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zebrafish P2X4 receptor structure, highlighting the impor-
tance of this lysine residue in the interaction of the receptor 
with ATP [27]. Alanine mutation of  Lys64 in the rat P2X7 
receptor or the corresponding lysine residue in other P2X 
receptors led to loss of receptor activation [35]. Notably, 
the corresponding residue in the chicken P2X7 receptor is 
threonine  (Thr64) [29].  Thr64 is expected to interact with 
ATP, but it remains to be verified whether this is the case 
and whether such an interaction is important for receptor 
activation. In all ATP-bound P2X receptor structures, the 
hydroxyl groups at positions 2′ and 3′ of the ribose face 
outwardly, indicating that ATP analogues with a bulky moi-
ety at these positions readily bind to the ATP-binding site. 
Consistently, 2′(3′)-O-(4-benzoylbenzoyl)ATP (BzATP) is 
known as a potent P2X receptor agonist. As discussed below, 
2′,3′-O-(2,4,6-trinitrophenyl)ATP (TNP-ATP) binds to the 
ATP-binding site as a competitive antagonist.
There is functional and structural evidence to indicate 
that additional residues in the ATP-binding pocket contrib-
ute in determining ATP sensitivity of the P2X7 receptors 
or receptor activation, as shown in the rat P2X7 receptor 
(Fig. 2b).  Arg276 and  Arg277 are in the lower body and highly 
conserved in P2X receptors. In the mouse P2X7 receptor, the 
charge-neutralising mutation R276A increased the ATP sen-
sitivity, and charge-conserving mutations R276K and R277K 
enhanced ATP-induced responses, without altering the ATP 
sensitivity [36, 37]. Similarly, the R276H mutation in the 
human P2X7 receptor, resulting from a non-synonymous 
single nucleotide polymorphism (NS-SNP), increased ATP-
induced responses [38].  Asp280 in the left flipper is mainly 
present in P2X7 receptors. The charge-neutralising muta-
tion D280A in the human P2X7 receptor led to increased 
ATP sensitivity [39].  Phe288 also in the left flipper is highly 
conserved in P2X7 receptors, except that it is replaced 
with another hydrophobic residue,  Tyr288, in the human 
P2X7 receptor. This residue is equivalent to the hydro-
philic  Ser275 in the human P2X3 receptor, which interacts 
with the α-phosphate group [32]. Such a local change may 
contribute to the lower ability of ATP to bind to the P2X7 
receptor. In the neighbouring subunit,  Lys193 in the lower 
body is positioned close to ATP. This residue is highly con-
served in P2X receptors, and the corresponding residue in 
the zebrafish P2X4 receptor,  Lys193, interacts indirectly with 
the α-phosphate group of ATP [27]. Alanine mutation of the 
corresponding residue  Lys188 in the rat P2X2 receptor led to 
dramatically reduced sensitivity to ATP [40]. The dorsal fin 
of P2X7 receptors is relatively shorter than that of other P2X 
receptors and lacks the hydrophobic residue corresponding 
to  Leu217 in the zebrafish P2X4 receptor that interacts with 
the adenine moiety of ATP [27]. Three hydrophobic resi-
dues,  Leu191 in the lower body and  Ile214 and  Ile228 in the 
dorsal fin, are oriented towards the ribose and adenine, and 
together generate a local hydrophobic milieu that may assists 
ATP binding in a similar manner as  Leu217. Both  Leu191 and 
 Ile228 are conserved in P2X7 receptors and  Ile214 is present in 
most of them. Consistently, L191P, another NS-SNP muta-
tion in the human P2X7 receptor, impaired ATP-induced 
current and dye uptake responses [41].  Lys145 in the head 
is conserved in mammalian P2X7 receptors but replaced by 
asparagine in the chick P2X7 receptor. The charge-neutral-
ising mutation K145A in the rat P2X7 receptor reduced its 
sensitivity to BzATP [42]. Finally,  Glu186 and  Asn187 in the 
right flipper, outside of the ATP-binding pocket, are highly 
conserved in P2X7 receptors, except that  Asn187 is replaced 
with aspartate in the chicken P2X7 receptor. NS-SNP muta-
tions in the human P2X7 receptor altering these residues 
affect receptor responses to agonist; E186K completely abol-
ished ATP-induced responses [41] and N187D reduced the 
BzATP sensitivity [43]. Thus, residues in the regions sur-
rounding the ATP-binding site, some being highly conserved 
in P2X receptors and others specific to P2X7 receptors, are 
important in determining the sensitivity of P2X7 receptors 
to ATP and BzATP, by directly supporting agonist binding 
to the ATP-binding site, or indirectly influencing their access 
to the ATP-binding site or agonist binding-induced confor-
mational changes for receptor activation.
Mammalian P2X7 receptors exhibit species differences 
in agonist sensitivity, most noticeably with the rat receptor 
being more sensitive to ATP and BzATP than the human, 
mouse, and dog receptors [7, 44–46]. The mouse P2X7 
receptor with the extracellular domain replaced with that of 
the rat P2X7 receptor displayed virtually the same agonist 
sensitivity as the rat P2X7 receptor, indicating the extracel-
lular domain is critical [44]. Further characterisation of the 
mouse P2X7 receptor carrying individual residues changed 
to the corresponding residues in the rat P2X7 receptor iden-
tified  Asn284, or  Asn284 together with  Lys127, as main deter-
minants for the greater sensitivity of the rat P2X7 receptor to 
ATP and BzATP, respectively.  Lys127 and  Asn284, located in 
the head or left flipper respectively, oversee the ATP-binding 
pocket (Fig. 2b). In P2X7 receptors of other species, position 
127 is occupied by alanine in mouse and chicken or threo-
nine in other species, and  Asn284 is also present in human, 
guinea pig, and rabbit but substituted with various residues 
in other species, consistent with a role for residues at these 
positions in impacting agonist access to the ATP-binding site 
in a species-dependent manner.
Therefore, a subset of highly conserved residues coordi-
nate ATP binding at the apex of an inter-subunit ATP-bind-
ing pocket in the P2X7 receptor, as in other P2X receptors. 
Additional residues in the ATP-binding pocket contribute to 
determining the agonist sensitivity of P2X7 receptors. How-
ever, there is still lack of a full understanding of the P2X7 
receptors that exhibit a much lower ATP sensitivity and also 
activation by ATP in the form of  ATP4− [4].
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Agonist‑induced conformational changes 
in the extracellular and transmembrane 
domains
Comparisons of the structures of the zebrafish P2X4, human 
P2X3, and rat P2X7 receptors in apo and ATP-bound states 
have disclosed considerable conformational changes accompa-
nying receptor activation, particularly in the extracellular and 
transmembrane domains [27, 30, 32], as illustrated in Figs. 1b 
and 2a for the rat P2X7 receptor. Agonist binding to the ATP-
binding site triggers the ATP-binding pocket to tighten. More 
specifically, the interaction of the ribose and adenosine with 
hydrophobic residues,  Ile214 and  Ile228 in the rat P2X7 recep-
tor, induces upward movement of the dorsal fin, and subse-
quent outward movement of the lower body that is connected 
to the dorsal fin. The interaction of  Phe288 in the lower body 
of the rat P2X7 receptor with the ribose and adenosine may 
impact such an outward movement of the lower body. The 
conformational change in the lower body causes enlargement 
of three lateral fenestrations adjacent to the membrane, which 
allow ions to enter into, or exit from, the transmembrane ion-
permeating pathway (Fig. 2a). The conformational changes in 
the extracellular domains eventually drive, via the connecting 
rods (Fig. 1a), relative movement of TM1 and TM2 α-helices 
and outward flexing of the TM2 α-helices leading to open-
ing of the ion-permeating pathway. Consistently, mutation of 
residues such as  Lys49 and  Phe322 in the β-sheets connecting 
the TM1 and TM2 α-helices altered activation of the rat P2X7 
receptor by BzATP [47].
While the structures reveal that the upper body remains 
overall relatively immobile, there is increasing functional 
evidence to support that conformational changes occur in 
the upper body during P2X7 receptor activation. Simul-
taneous cysteine substitutions of  Lys81 and  Val304 in the 
human P2X7 receptor hindered receptor activation that was 
reversed by treatment with the reducing agent dithiothreitol 
(DTT) [48], indicating that these two residues or positions 
are in close vicinity in the closed state and move apart 
distantly in the open state. Replacement of  Val87 in the 
human P2X7 receptor with the corresponding isoleucine in 
the rat P2X7 receptor enhanced current responses to ATP 
and BzATP [49], suggesting that residue at this position 
influences the local conformational change differently in 
the rat and human receptors. Moreover, as discussed below, 
the structures of the giant panda P2X7 receptor reveal an 
allosteric antagonist-binding pocket formed by the upper 
body that closes during receptor activation [28].
The transmembrane ion‑permeating 
pathway
One principal function of P2X receptors, including the 
P2X7 receptor, is to act as an ATP-gated cation-permeable 
channel. As mentioned above, the three TM2 α-helices 
constitute the transmembrane ion-permeating pathway in 
the centre of the receptor complex (Fig. 1b). In the apo 
structure of the rat P2X7 receptor,  Asn332,  Val335,  Ser339, 
and  Ser342 in the extracellular end of the TM2 α-helix 
(Fig.  3a) face the external vestibule, and  Ser339 and 
 Ser342 define the extracellular and intracellular bounda-
ries, respectively, of the ion-occluding gate (Fig. 3b), at 
which the pore has a maximal radius of 0.1 Å [30]. The 
structures of the giant panda P2X7 receptor, determined 
in the antagonist-bound state, also reveal that the region 
between  Ser339 and  Ser342 forms the gate of the ion-per-
meating pathway in the closed state (Fig. 3c). Single chan-
nel recording in conjunction with the substituted cysteine 
accessibility method suggests that the gate of the human 
P2X7 receptor ion channel is located at the region sur-
rounding  Ser342 [50]. In the ATP-bound structure of the 
rat P2X7 receptor (Fig. 3d), the TM2 α-helices move apart 
from each other, opening the ion-permeating pathway con-
tinuously across the membrane with a minimal radius of 
2.5 Å at  Ser342, and  Ser339 is rotated away from the centre 
of the external vestibule (Fig. 3d). In the human P2X7 
receptor, simultaneous introduction of cysteine substitu-
tion at  Asp48 and  Ile331, located in the extracellular end 
of the TM1 and TM2 α-helices, respectively, prevented 
receptor activation, which was rescued by treatment with 
DTT [48]. Thus, these two residues or positions are in 
close proximity in the closed state and distance signifi-
cantly from each other in the open state, supporting occur-
rence of considerable conformational changes in the exter-
nal vestibule.
The apo and ATP-bound structures of the rat P2X7 
receptor suggest that the intracellular part or the internal 
vestibule of the ion-permeating pathway remains widely 
open, even in the closed state, and is further connected 
to large spaces between two TM2 α-helices, named the 
cytoplasmic fenestrations [30]. It has been proposed that, 
in the open state, permeant ions leave the internal vesti-
bule via the cytoplasmic fenestrations to reach the cytosol 
[30]. However, the structure of the chicken P2X7 recep-
tor reveals noticeably different arrangements of the ion-
permeating pathway, particularly the internal vestibule. 
This structure was determined with TNP-ATP bound to 
the ATP-binding site and is thought to be in an incom-
pletely activated state, because the overall conformation 
of the extracellular domain more closely resembles that 
of the zebrafish P2X4 and human P2X3 receptors in the 
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ATP-bound state rather than in the apo state [29]. The pore 
region surrounding  Ser326 and  Ala329 in the chicken P2X7 
receptor (Fig.  3e), corresponding to  Ser339 and  Ser342 
in the rat and giant panda P2X7 receptors (Fig. 3b–c), 
widely opens and is permissive to ion flow. In striking 
contrast with the exceptionally spacious intracellular part 
of the ion-permeating pathway in the rat P2X7 receptor 
structure (Fig. 3b), the internal vestibule lined by  Ile337, 
 Met340,  Cys341, and  Ler344 in the chicken P2X7 receptor, 
corresponding to  Cys350,  Leu353,  Ile354, and  Thr357 in the 
rat P2X7 receptor or  Phe350,  Phe353,  Leu354, and  Thr357 in 
the human P2X7 receptor (Fig. 3a), is highly restricted, 
with the pore radius being < 0.3 Å at  Met340 and  Cys341 
(Fig. 3e). Such structural features strongly suggest that 
the internal vestibule plays a significant role in defining 
the ion channel function, which is indeed well supported 
by functional studies of the human and rat P2X7 receptors 
carrying mutations in the intracellular part of the TM2 
α-helix [41, 51, 52].  Ala348 in the human P2X7 receptor 
is equivalent to  Thr348 in the rat P2X7 receptor, corre-
sponding to  Val335 in the chicken P2X7 receptor (Fig. 3a). 
A348T, a NS-SNP mutation in the human P2X7 receptor, 
enhanced ATP-induced current responses, whereas intro-
duction of reciprocal mutation T348A in the rat P2X7 
receptor reduced, ATP-induced current responses [51]. 
Further characterisation of the human P2X7 mutant recep-
tor with  Ala348 replaced by different residues indicates that 
the current amplitude was overall inversely related to the 
size of the side chain of introduced residues, supporting 
the notion that the residue at this position considerably 
influences the ion flow through the internal vestibule. 
Replacement of  Phe353 in the human P2X7 receptor with 
 Leu353 in the rat P2X7 receptor also increased ATP-
induced currents and, conversely, substitution of  Asp356 
in the human P2X7 receptor with  Asn356 in the rat P2X7 
receptor decreased ATP-induced currents. None of the 
mutations altered the agonist sensitivity [51]. These results 
also suggest that the different residues at positions 348 and 
353, as well as at position 87 in the upper body discussed 
above, contribute to the different current responses of the 
human and rat P2X7 receptors. In addition, introduction 
of T348K, D352K, or D352N in the rat P2X7 receptor to 
add positive charges or neutralise existing negative charges 
at these positions conferred the resulting ion channel with 
Fig. 3  The transmembrane ion-permeating pathway. a Alignment 
of the TM2 sequences from human, rat, mouse, giant panda, and 
chicken P2X7 receptors. b–c The arrangements of the TM1 and 
TM2 α-helices in the rat (b) and giant panda (c) P2X7 receptor in the 
closed state, viewed from parallel to the membrane (top) or the intra-
cellular side (bottom). Q332, V335, S339, and S342 in the extracel-
lular part of the TM2 α-helix line the external vestibule in the closed 
state, with S339 and S342 located at the extracellular and intracel-
lular ends of the ion-restricting gate. d The arrangements of the TM1 
and TM2 α-helices in the rat P2X7 receptor in the ATP-bound and 
open state, viewed from parallel to the membrane (top) or the intra-
cellular side (bottom). Movement of the TM2 α-helices apart from 
each other opens the ion-permeating pathway across the membrane 
with the pore at S342 remaining the narrowest part. The internal ves-
tibule is wide and connected the cytoplasmic fenestrations between 
two TM2 α-helices, and permeant ions leave the internal vestibule via 
cytosolic fenestrations to reach the cytosol. e The arrangements of the 
TM1 and TM2 α-helices in the TNP-ATP bound chicken P2X7 recep-
tor, viewed from parallel to the membrane (top) or the intracellular 
side (bottom). The internal vestibule is restricted at M340 and C341
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measurable chloride permeability [52]. Collectively, func-
tional studies provide evidence to support the importance 
of the intracellular part of the TM2 α-helix in determining 
the permeability of the P2X7 receptor ion channel. Evi-
dently, further investigations are required to resolve the 
emerging discrepancies to achieve a clear understanding 
of the ion-permeating pathway in the P2X7 receptor in the 
closed and open states.
The C‑terminal cysteine‑rich domain 
as an anchor to prevent receptor 
desensitisation
Agonist-induced current responses of P2X receptor ion 
channels exhibit remarkably different desensitisation kinet-
ics. For example, the P2X1 and P2X3 receptors desensitise 
extremely fast, losing current responses within 1 s, and the 
P2X2, P2X4, and P2X5 receptors also desensitise but rela-
tively slowly; however, the P2X7 receptor does not [53]. In 
addition, the P2X7 receptor exhibits striking sensitisation 
or facilitation, with the current responses increasing upon 
prolonged or repeated agonist exposure. There is evidence 
to support an important role for intracellular domains in 
receptor sensitisation or facilitation [39, 54–57]. Functional 
and structural studies consistently point to the P2X7-spe-
cific C-terminus, particularly the CRD, for its role in pre-
venting receptor desensitisation. The human P2X7 recep-
tor with deletion of the CRD  (Cys362-Ala379) desensitised 
considerably, and, conversely, the human P2X1 or human 
P2X2 receptor with the CRD from the human P2X7 recep-
tor inserted in the C-terminus exhibited substantially less 
desensitisation [39]. It is proposed, based on the structures 
of the human P2X3 receptor, particularly in the ATP-bound 
open and desensitisation states, that receptor desensitisa-
tion is associated with breakdown of the cytoplasmic cap 
and subsequent rearrangement of the TM2 α-helices. This 
may result in the closure of the ion-permeating pathway at 
 Val344 in the human P2X3 receptor [32], which corresponds 
to  Val349 in the rat P2X7 receptor or  Thr336 in the chicken 
P2X7 receptor (Fig. 3a). As introduced above, the rat P2X7 
receptor structures reveal that the P2X7-specific CRD, 
which connects the TM2 and the cytoplasmic cap, are pal-
mitoylated at multiple residues [30]. As shown in the human 
P2X7 receptor [39], the rat P2X7 receptor with deletion of 
the CRD exhibited strong desensitisation [30]. Furthermore, 
there was considerable receptor desensitisation in the rat 
P2X7 receptor with simultaneous alanine substitution of all 
palmitoytable residues in the CRD  (Ser360,  Cys362,  Cys363, 
 Cys371,  Cys373,  Cys374, and  Cys377). Taken together, these 
structural and mutational studies support the idea that the 
P2X7-specific CDR acts as the C-cys anchor to stabilise 
the cytoplasmic cap and TM2 α-helices and thereby prevent 
receptor desensitisation.
The mechanistically enigmatic large pore 
formation
Prolonged or repeated receptor activation triggers formation 
of large pores across the plasma membrane that allow per-
meation of molecules of up to 900 Da. As described above, 
this functional property defines the P2X7 receptor, even 
though it has been reported that activation of some other 
P2X receptors can also induce large pore formation, albeit 
less consistently and profoundly. Large pore formation can 
be measured, most commonly by monitoring intracellular 
accumulation of extracellular positively charged fluorescent 
dyes that are considerably larger than small cations, such 
as YO-PRO-1 (378 Da) and ethidium (314 Da) [52]. Accu-
mulating evidence supports the importance of this receptor 
functionality in ATP-induced P2X7-mediated regulation of 
physiological and pathological processes [59–63]. However, 
the mechanisms underlying large pore formation remain 
poorly defined [64, 65]. Attention has been drawn to the 
unique C-terminus of the P2X7 receptor. Indeed, the seminal 
study reporting the rat P2X7 receptor showed that trunca-
tion of the extra C-terminus in the P2X7 receptor abolished 
its ability to induce large pore formation without affecting 
its ability to form functional ion channel [5]. Similarly, 
the human P2X7B receptor, an alternative splice variant 
containing additional 18 residues inserted after  Leu346 but 
without the last 249 residues in the C-terminus, functions as 
an ATP-gated ion channel, but its activation cannot induce 
dye uptake [66]. The mouse P2X7 receptor carrying  Pro451 
or  Leu451 in the C-terminus shows virtually the same ion 
channel function, but only activation of the receptor har-
bouring  Pro451, but not  Leu451, can trigger large pore forma-
tion [60, 67]. Deletion of the CRD  (Cys362-Val380) in the rat 
P2X7 receptor increased BzATP-induced dye uptake [68] 
but removal of the CRD  (Cys362-Ala379) in the human P2X7 
receptor inhibited BzATP-induced dye uptake [39]; the exact 
reason for such species-dependence remains unclear. Intro-
duction of point mutations in the N-terminus in the human 
P2X7 receptor also impaired BzATP-induced dye uptake 
[39]. Thus, both the intracellular domains, particularly the 
C-terminus, can influence the ability of P2X7 receptors to 
induce large pore formation.
There is some evidence to suggest that the P2X7 receptor 
ion channel itself forms the large pore, and, furthermore, 
sustained receptor activation may trigger an increase in the 
size of the transmembrane ion-permeating pathway.  Gly345 
in the TM2 α-helix (Fig. 3a) is a completely conserved resi-
due in P2X receptors that is thought to offer structural flex-
ibility for conformal changes in the ion-permeating pathway. 
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In the rat P2X7 receptor, tyrosine substitution of  Gly345 
abolished agonist-induced dye uptake, without affecting 
 Ca2+ influx through the open ion channel [59], and alanine 
replacement resulted in significant effects on both current 
and YO-PRO-1 uptake responses [69]. Further supporting 
evidence was provided by examining the permeability of 
the rat P2X7 receptor ion channel [52]. Membrane poten-
tial is known to be a driving force for the flow of small 
cations through the open ion channel, and, similarly, YO-
PRO-1 uptake exhibited strong voltage-dependence, becom-
ing progressively less with the membrane potential shifting 
towards from negative to positive [52]. As discussed above, 
the study showed that the rat P2X7 receptor ion channel car-
rying T348K or D352N mutation in the intracellular end of 
the TM2 α-helix displayed measurable chloride permeabil-
ity. These mutations also led to enhanced entry of negatively 
charged fluorescein isothiocyanate (387 Da) and reduced 
entry of positively charged ethidium. Moreover, exposure of 
the wide-type (WT), G345C, or T348C mutant receptor to 
2-((biotinoyl)amino)ethyl methanethiosulfonate (MTSEA-
biotin; 382 Da) in the closed state had no effect on ATP-
induced currents and ethidium uptake [52]. There was also 
no effect from exposure of the WT receptor in the open state 
to MTES-biotin. However, MTSEA-biotin modification of 
introduced cysteines, when the mutant receptor was in the 
open state, reduced ATP-induced currents mediated by the 
G345C or T348C mutant receptor, and ATP-induced ethid-
ium uptake shown at the G345C mutant receptor [52]. Simi-
larly, when the WT receptor in the closed or open state or the 
G345C mutant receptor in the closed state were exposed to 
the neutral and larger MTSR (696 Da), there was no effect, 
and, in contrast, exposure of the G345C mutant receptor in 
the open state rapidly inhibited ATP-induced currents. These 
results support the concept that the P2X7 receptor ion chan-
nel in the open state can permeate nanometre-sized dyes, in 
addition to small cations [52].
Analysis of the human P2X7 receptor at single chan-
nel level indeed also supports that the P2X7 receptor ion 
channel is permeable to large organic cations, including 
N-methyl-D-glucamine (NMDG; 196 Da), with the perme-
ability inversely related with the size of permeant cations 
but, importantly, there is no indication of change in the 
permeability during prolonged receptor activation [70]. 
Similarly, modification by methanethiosulfonates of intro-
duced cysteines in the TM2 α-helix altered human P2X7 
receptor single channel conductance and open probability, 
but such alterations remained unchanged during extended 
recording up to 30 min [50]. As discussed above, the ion-
permeating pathway in the ATP-bound structure of the rat 
P2X7 receptor [30] is sufficiently wide to permit passage 
of small physiological cations but seems too narrow to 
permeate large organic cations or nanometre-sized fluo-
rescent dyes. To conclude, the mechanisms for the large 
pore-inducing functionality of P2X7 receptors continue to 
remain enigmatic.
The orthosteric TNP‑ATP binding site
TNP-ATP is a synthetic ATP analogue with a trinitrophenyl 
group attached to the ribose moiety at 2′ and 3′ positions. 
An early study by whole-cell recording of agonist-induced 
currents demonstrated that TNT-ATP preferentially inhibits 
P2X1- or P2X3-contaning receptors with an  IC50 of < 10 nM 
and may act as a non-competitive antagonist [71]. The same 
study also showed that TNT-ATP has a considerably low 
sensitivity for the rat P2X7 receptor (> 30 μM) [71], whereas 
a recent study reports that TNP-ATP more potently inhibits 
the chicken P2X7 receptor, with an  IC50 of 3.6 μM [29]. 
Recent studies have determined the structures of the human 
P2X3 [32] and chicken P2X7 receptors [29] in the presence 
of TNP-ATP, revealing that TNP-ATP binds to the ATP-
binding site in both receptors.
In the human P2X3 receptor, ATP binding is coordinated 
by  Lys63,  Lys65,  Thr172,  Asn279,  Arg281, and  Lys299 in the 
ATP-binding site, as described above by the corresponding 
residues,  Lys64,  Lys66,  Thr189,  Asn292,  Arg294, and  Lys311, in 
the rat P2X7 receptor (Fig. 2b), and in addition, by  Ser275 
in the left flipper, corresponding to  Phe288 in the rat P2X7 
receptor [32]. Namely,  Lys63 interacts with the triphosphate 
groups,  Lys65,  Arg281, and  Lys299 with the γ-phosphate 
group,  Asn279 with the β-phosphate group,  Ser275 with the 
α-phosphate group, and  Thr172 with adenine. As anticipated, 
TNP-ATP interacts with the ATP-binding site via the ATP 
moiety, with the trinitrophenyl (TNP) moiety outward-fac-
ing. However, the ATP moiety adopts a distinct U-shaped 
configuration and forms different hydrogen bond networks. 
 Asn279,  Arg281, and  Lys299 interact with the γ-phosphate 
group,  Lys65 with the α-phosphate group, and  Lys63 and 
 Thr172 with the adenine. Furthermore, TNP-ATP interacts 
with  Phe174 in the lower body, and, indirectly via  Mg2+, with 
 Asp158 in the head. These two residues are mainly present in 
the P2X1 and P2X3 subunits, suggesting their importance in 
defining high affinity binding of TNP-ATP to the P2X1- or 
P2X3-containing receptors [32].
The structure of the chicken P2X7 receptor show different 
interactions of TNP-ATP with the ATP-binding site [29]. 
Interestingly but not surprisingly, as introduced above, TNP-
ATP binding induces significant conformational changes 
in the extracellular domain, which are nonetheless insuf-
ficient to open the ion-permeating pathway. As shown in 
Fig. 4a, in the chicken P2X7 receptor, the ATP moiety inter-
acts with  Thr64,  Lys66,  Thr177, and  Lys298, corresponding to 
 Lys64,  Lys66,  Thr189, and  Lys311 in the ATP-binding site in 
the rat P2X7 receptor (Fig. 2b), and also with  Lys236 in the 
upper body, equivalent to  Asn248 in the rat and human P2X7 
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receptors.  Thr64,  Lys66, and  Thr177 form hydrogen bonds with 
the adenine,  Lys236 with the γ-phosphate group, and  Lys298 
with both the γ-phosphate and β-phosphate groups (Fig. 4a). 
Unlike in the human P2X3 receptor, the TNP moiety also 
participates in interactions with the chicken P2X7 receptor 
by forming hydrogen bonds between the three  NO2 groups 
with  Lys66 in the lower body,  Thr112 in the head, and  Thr202 
in the dorsal fin, respectively. A threonine corresponding 
to  Thr112 is also present in the human P2X7 receptor and 
replaced with serine in the rat P2X7 receptor, whereas the 
residue corresponding to  Thr202 is variable, with isoleucine 
in the human and rat P2X7 receptors. In addition,  His131 in 
the head and  Tyr274 in the left flipper are positioned close to 
TNP-ATP.  His131 is replaced with glutamine in the human 
and rat P2X7 receptors, and tyrosine corresponding to  Tyr274 
is also found in the human P2X7 receptor and substituted 
with phenylalanine  (Phe288) in the rat P2X7 receptor. It is 
unclear, but interesting, to examine how these residues deter-
mine the difference in the sensitivity of the chicken and rat 
P2X7 receptors to TNP-ATP.
The inter‑subunit allosteric binding pocket 
for chemically diverse antagonists
Extraordinary efforts in medicinal chemistry driven by the 
interest in the P2X7 receptor as a therapeutic target have 
led to the discovery of numerous specific and potent P2X7 
antagonists, with some exhibiting striking species differ-
ences [72–75]. Surprisingly, accumulating structural and 
functional evidence supports a common action mechanism 
for many of these chemically diverse antagonists via binding 
to the same inter-subunit allosteric binding pocket.
A74003, A804598, AZ10606120, and JNJ47965567 rep-
resent four structurally distinct mammalian P2X7 receptor 
antagonists. Competitive ligand binding analysis in a pre-
vious study suggests significantly overlapping binding of 
A804598 and JNJ47965567 [76]. GW791343 is an antago-
nist at the human and dog P2X7 receptors, but acts as a 
positive allosteric modulator at the rat P2X7 receptor [45, 
46]. All of them are recently shown to be antagonists at 
the giant panda P2X7 receptor [28]. Structures of the giant 
panda P2X7 receptor, without the intracellular domains, 
in the presence of each of these antagonists reveal a com-
mon antagonist-binding pocket adjacent to the ATP-binding 
pocket, demonstrating allosteric and non-competitive antag-
onism. This allosteric antagonist-binding pocket is formed 
mainly by β4, β13 and β14 in the upper body (Fig. 1a) of two 
neighbouring subunits, as illustrated for A74003 binding to 
the giant panda P2X7 receptor (Fig. 4b). The pocket is lined 
by both hydrophobic and hydrophilic residues, including 
 Phe88,  Phe95,  Phe103,  Met105,  Phe108,  Lys110,  Glu305,  Ile310, 
and  Val312. Alanine mutation of the hydrophobic but not 
the hydrophilic residues in the giant panda P2X7 recep-
tor reduced the antagonist sensitivity (Table 1), suggesting 
that antagonist binding is mainly mediated by hydropho-
bic interactions. In addition, the effects of mutating indi-
vidual hydrophobic residues depend strongly on individual 
antagonist (Table 1), reflecting their varying chemical struc-
tures and, thus, different interactions with residues in the 
allosteric binding pocket. These hydrophobic residues are 
either highly conserved or replaced by another hydrophobic 
residue in other mammalian P2X7 receptors; for example, 
 Phe95 and  Val312 are replaced by  Leu95 and  Ala312 in the 
rat P2X7 receptor, respectively. In the zebrafish P2X4 and 
human P2X3 receptors, the equivalent inter-subunit cavity 
formed by the β13 and β14 strands in the upper body also 
contains several hydrophobic residues, but the turret-like 
structure, corresponding to the antagonist-binding pocket 
in the giant panda P2X7 receptor, appears too narrow to 
Fig. 4  The orthosteric and allosteric antagonist-binding pockets. a 
TNP-ATP binding to the ATP-binding site in the chicken P2X7 recep-
tor. The ATP moiety interacts with T64, K66, T177, and K298 in the 
ATP-binding site, and also K236 in the upper body. The TNP moiety 
interacts, through its three  NO2 groups, with K66 in the lower body, 
T112 in the head, and T202 in the dorsal fin. H131 in the head and 
Y274 in the lower body are positioned close to TNP-ATP. b The 
allosteric binding pocket for chemically diverse P2X7 receptor antag-
onists in the giant panda P2X7 receptor, as illustrated for A740003 
and the key hydrophobic residues that coordinate A740003 binding
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accommodate even the smallest antagonist, A804598. These 
differences suggest that the size and shape of this allosteric 
binding pocket, as well as the interactions with P2X7-spe-
cific residues, are vital in determining the specific and high 
binding affinity binding of these antagonists to the giant 
panda P2X7 receptor [28]. This notion is further supported 
by P2X7-specific modification of cysteines introduced in the 
allosteric binding pocket [28]. Moreover, state-dependent 
cysteine modification of residues in the allosteric binding 
pocket in the giant panda P2X7 receptor suggests that the 
allosteric binding pocket is tightened during receptor acti-
vation. Such a finding has led to the proposal of a mecha-
nism of antagonism for these P2X7 antagonists, in which 
occupancy of the allosteric binding pocket hinders the ATP 
binding-induced conformational changes in the upper body, 
which are required for receptor activation [28].
Studies combining structural modelling of the giant 
panda P2X7 receptor, ligand docking, site-directed 
mutagenesis, and functional characterisation provide 
evidence to suggest that this allosteric binding pocket 
also underpins the specific and potent inhibition by 
AZ10606120, A74003, and A438079 of the human P2X7 
receptor [77, 78]. Introduction of point mutations of resi-
dues in the entrance  (Lys110,  Val304, and  Glu305), middle 
 (Phe88,  Asp92,  Met105,  Phe108,  Lys297,  Tyr298,  Ile310, and 
 Val312), and bottom  (Thr90,  Ala91,  Tyr93,  Thr94,  Phe95, 
 Pro96,  Leu97, and  Phe103) of the above-described allos-
teric antagonist-binding pocket in the human P2X7 recep-
tor reduced (F88A, T90V, D92A, Y93A, T94V, F103A, 
and M105A) or increased (K110Y, K297G, V304C, and 
E305A) the sensitivity to AZ10606120 (Table 1) [77]. 
It is noted that introduction of F88A, M105A, K110Y, 
or E305A mutation in the giant panda P2X7 receptor 
resulted in no change in, whereas V312A mutation in the 
human P2X7 receptor was with no significant effect on, 
the sensitivity to AZ10606120 (Table 1). It remains to be 
confirmed whether such differences reflect the structural 
differences in the interactions of AZ10606120 with the 
allosteric binding pocket in the giant panda and human 
P2X7 receptors. Introduction of above-described muta-
tions in the allosteric binding pocket caused a reduction 
(F88A, T90V, A91C, D92A, T94V, F95A, P96A, L97P, 
F103A, M105A, F108C, Y298A, and V312A) or increase 
(K297G) in the sensitivity to A740003 (Table 1) [77]. 
These results indicate some differences in mutational 
effects (F95A and F108C on the sensitivity of the giant 
panda and human P2X7 receptors to A740003) (Table 1). 
Introduction of such single mutations also resulted in 
a reduction (F88A, T90V, A91C, D92A, Y93A, T94V, 
F95A, P96A, F103A, F108C, Y298A, I310A, and 
V312A) or increase (L97P, K297G, V304C, and E305A) 
in the sensitivity to A438079 (Table 1) [77].
Table 1  Summary of mutational effects on the sensitivity of the giant panda and human P2X7 receptors to chemically diverse antagonists
Mutations of the allosteric binding pocket in the giant panda P2X7 receptor (a) or the human P2X7 receptor (b) reduce, or increase (c), the sensitiv-
ity to indicated antagonists. 1, 2, and 3 denote 10-, 100-, and 1000-fold change, respectively. NS, no significant change; -, not examined. Com-
pletely or highly conserved residues are shown in bold, and the position of residues in the entrance, middle, and bottom of the allosteric binding 
pocket indicated. Data extracted from [28, 77, 78, 80]
Mutation Position A74003a A74003b A804598a AZ10606120a AZ10606120b JNJ47965567a GW791343a A438079b AZ11645373b
K110Y Entrance NS NS NS NS  > 1.0c  ~ 1.0 NS NS  > 1.0c
V304C Entrance - NS - -  < 1.0c - -  > 1.0c -
E305A Entrance NS NS NS NS  < 1.0c NS NS  < 1.0c NS
F88A Middle  > 1.0  > 1.0  > 1.0 NS  > 1.0  > 1.0 NS  ~ 3.0  > 1.0
D92A Middle -  ~ 2.0 - -  ~ 3.0 - -  > 3.0  > 1.0
M105A Middle  > 1.0  > 2.0  > 1.0 NS  ~ 2.0  > 1.0 NS NS NS
F108C Middle NS  > 1.0  > 1.0 NS NS  > 1.0 NS 1.0  < 1.0
K297G Middle -  < 1.0c - -  > 1.0c - -  > 1.0c NS
Y298A Middle −  > 1.0 - - NS - -  < 1.0 NS
I310A Middle NS NS NS NS NS NS NS  < 1.0  > 1.0
V312A Middle  < 1.0  < 1.0 NS  ~ 1.0 NS  ~ 1.0  < 1.0  < 1.0  < 1.0
T90V Bottom -  < 1.0 - -  > 1.0 - -  < 1.0  > 1.0
A91C Bottom -  > 1.0 - - NS - -  > 1.0  > 1.0
Y93A Bottom - NS - -  < 1.0 - -  < 1.0  < 1.0
T94V Bottom -  < 1.0 - -  < 1.0 - -  > 3.0  > 3.0
F95A Bottom NS  > 1.0  > 2.0 NS NS NS -NS  > 3.0  > 3.0
P96A Bottom -  < 1.0 - - NS - -  > 1.0  > 3.0
L97P Bottom -  < 1.0 - - NS - -  < 1.0c  > 1.0
F103A Bottom  < 1.0  < 1.0  > 1.0  > 1.0  > 1.0  > 1.0  > 1.0  > 3.0  > 1.0
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There is also evidence to suggest that AZ11645373, 
KN-62, SB203580, ZINC58368839, calmidazolium, and 
brilliant blue G (BBG) bind to this same allosteric binding 
pocket in the human P2X7 receptor. All these antagonists 
are known to preferentially inhibit the human P2X7 recep-
tor, except BBG which antagonises both the human and rat 
P2X7 receptors. Structural modelling of the human and rat 
P2X7 receptors on the zebrafish P2X4 receptor and sub-
sequent molecular docking suggest that of AZ11645373, 
KN-62, and SB203580 bind to a pocket in close proxim-
ity to the ATP-binding site in the human P2X7 recep-
tor [79]. This antagonist-binding pocket is located at the 
interface of two adjacent subunits in the close vicinity of 
the α2-helix and β13 and β14 in the upper body, similar to 
the allosteric binding pocket described in the giant panda 
P2X7 receptor [28]. More specifically, several residues 
were predicted to contact, or influence the orientation of, 
the docked antagonists. Particularly,  Phe95 in the human 
P2X7 receptor forms pi-stacking interactions with aromatic 
rings in antagonists, which is lost in the rat P2X7 receptor 
containing  Leu95, explaining the results that replacement 
of  Phe95 in the human P2X7 receptor with  Leu95 in the rat 
P2X7 receptor reduced the sensitivity to KN-62 [45] and 
AZ11645373 [80]. Leucine is also present in the guinea pig 
P2X7 receptor that shows a comparable KN-62 sensitivity to 
the human P2X7 receptor, indicating that other residues are 
importantly involved in determining the species-dependent 
sensitivity of KN-62. The approach combining structural 
modelling, molecular locking, mutagenesis, and functional 
characterisation described above to elucidate the binding 
site for AZ10606120, A74003, and A438079 has been 
recently applied to examine the interactions of AZ11645373, 
ZINC58368839, KN-62, calmidazolium, and BBG with the 
human and rat P2X7 receptors [80]. Single mutation of resi-
dues in the allosteric binding pocket discussed above led 
to strong loss (T94V, F95A, and P96A), reduction (F88A, 
T90V, A91C, D92A, Y93A, L97P, F103A, F108C, I310A, 
and V312A), or increase (K110Y) in the sensitivity of the 
human P2X7 receptor to AZ11645373 (Table 1) [80]. The 
study further examined the human P2X7 receptor carrying 
substitution of  Ser86 at the entrance,  Phe108 and  Val312 in the 
middle, and  Phe95 in the bottom of the allosteric binding 
pocket with the equivalent  Gly86,  Tyr108,  Ala312, and  Leu95 
in the rat P2X7 receptor, and also the rat P2X7 receptor 
harbouring reciprocal mutations. While reciprocal mutations 
of positions 86 and 108 resulted in no significant effect, the 
F95L or V312A mutant human P2X7 receptor was ~ 250-
fold and ~ 20-fold less sensitive to AZ11645373 and, con-
versely, the L95F or A312V mutant rat P2X7 receptor exhib-
ited an AZ11645373 sensitivity similar to the wide-type 
human P2X7 receptor. These results support that residues 
at positions 95 and 312 are critical in determining the differ-
ence in AZ11645373 sensitivity of the human and rat P2X7 
receptors. ZINC58368839, identified by virtual screening 
of the ZINC chemical database against the extended ATP-
binding pocket in the human P2X7 receptor structural model 
generated using the zebrafish P2X4 receptor, antagonises 
the human P2X7 receptor with a potency of micromolar 
concentrations [81]. ZINC58368839 has a similar size and 
is predicted to occupy the same allosteric binding pocket 
as AZ11645373. The human P2X7 receptor with D92A or 
F103A mutation became insensitive to ZINC58368839. 
KN-62, calmidazolium, and BBG are approximately twice 
as large as AZ11645373 but, nonetheless, can be docked into 
the same allosteric pocket in the human P2X7 receptor. Con-
sistently, introduction of T90V, D92A, F103A, or V312A 
mutations in the human P2X7 receptor largely abolished or 
strongly attenuated the sensitivity to KN-62, calmidazolium, 
and BBG [80].
In summary, structural and functional studies provide 
evidence that consistently supports a common inter-subu-
nit allosteric binding pocket for several chemically diverse 
P2X7 receptor antagonists. The size of this pocket and 
interactions with residues lining the pocket are critical in 
determining the specific and high affinity action of these 
antagonists. The differences in antagonist-interacting resi-
dues contribute to the structural basis underpinning species-
dependent antagonist sensitivity of P2X7 receptors.
Concluding remarks
Over the past, more than two decades since molecular identi-
fication of the P2X7 receptor, remarkable progress has been 
made in our understanding of the receptor structure–function 
relationships, as well as its role in mediating ATP-induced 
purinergic signalling in diverse physiological and pathologi-
cal processes. In particular, recent breakthroughs in struc-
tural biology have allowed revisiting of earlier mutagenesis 
and functional studies and facilitated further studies. As 
discussed above, combined efforts have led to important 
insights into the structural basis for the functional properties 
of the P2X7 receptor, including ATP binding, ion permea-
tion, and mechanism of action by chemically diverse P2X7 
receptor antagonists. The P2X7 receptor, despite disappoint-
ing outcomes from early clinical testing of P2X7 receptor 
antagonists for the treatment of rheumatoid arthritis, remains 
an attractive therapeutic target, with promising potential in 
the development of therapeutics for a diversity of debili-
tating conditions. Evidently, increased understanding of 
the structure–function relationships of the P2X7 receptor 
offers an exciting opportunity to develop structure-guided 
approaches to develop P2X7-specific antagonists, particu-
larly negative allosteric modulators to tune down the ele-
vated expression and activity of the P2X7 receptor that are 
often causatively associated with pathological conditions. It 
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is worth pointing out that more efforts are required to pro-
vide a full understanding at the molecular level of the unique 
functional properties of the P2X7 receptors.
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